Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Cost-Effectiveness Analysis | Policy/Regulation | Mental Health | Costing Methods | Health Outcomes | Evidence Synthesis | Benefit-Cost Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Health Systems | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
ArticlePublication 2018Cost-Effectiveness of Strategies to Prevent Road Traffic Injuries in Eastern Sub-Saharan Africa and Southeast Asia: New Results from WHO-CHOICE
The authors applied a generalized cost-effectiveness analysis (GCEA) approach, applying a null reference case, in …
The authors applied a generalized cost-effectiveness analysis (GCEA) approach, applying a null reference case, in which the effects of currently implemented interventions were subtracted from current rates of burden, in order to identify the most efficient package of interventions that could be applied to Road Traffic Injuries (RTIs). They used a population model to estimate costs and effectiveness of interventions over a 100 year time frame in eastern sub-Saharan Africa and Southeast Asia. All heath…
Cost-Effectiveness Analysis | State-Transition | Policy/Regulation | Injuries/Accidents | Culture/Society | Science/Technology | Sub-Saharan Africa | Asia & Pacific -
ReviewPublication 2017Model-Based Economic Evaluation of Treatments for Depression: A Systematic Review
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies …
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies evaluating the cost-effectiveness of treatments for depression and examine the appropriateness of different modelling technique for simulating the natural course of depression. The review yielded 41 model-based studies, of which 21 used decision trees (DTs), 15 used cohort-based state-transition Markov models (CMMs), two used individual-based state-transition models (ISMs), and three used discrete-event simulation (DES) models. Just over half of the…
Cost-Effectiveness Analysis | State-Transition | Mental Health | Mathematical Models | Microsimulation | Health/Medicine -
Resource PackPublication, Teaching Resource 2017Resource Pack: U.S. Opioid Epidemic
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public …
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public health crisis, requiring an urgent coordinated response and innovative scientific solutions. This resource pack was curated for educators and students interested in how decision analytic methods and tools can be applied to the problem of opioid addiction.
Cost-Effectiveness Analysis | Policy/Regulation | Mental Health | Preferences/Values | Evidence Synthesis | Mathematical Models | Decision Analysis | Chronic Disease/Risk | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine | North America | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ArticlePublication 2016Cost-Effectiveness of Collaborative Care for Depression and Comorbid Diabetes or CVD
This article, published in BMJ Open, presents an economic model that combines a decision tree …
This article, published in BMJ Open, presents an economic model that combines a decision tree and a Markov cohort model to investigate the long-term cost-effectiveness of collaborative care versus usual care for individuals with depression and comorbid diabetes and/or cardiovascular disease. Data from the COINCIDE trial informs the model input parameters. The COINCIDE trial is a randomized controlled trial of collaborative care versus usual care that enrolled 387 participants from 36 primary care general practices…
Cost-Effectiveness Analysis | State-Transition | Mental Health | Chronic Disease/Risk | Health/Medicine | Europe -
ReviewPublication 2016Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases …
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases (NCDs) on development and economic growth in the countries of Latin America and the Caribbean (LAC). This collection of manuscripts examines the complex interplay among NCDs, health expenditures and financial investments in health, poverty, and inequities, using up-to-date information and evidence from the LAC region. There is compelling proof that NCDs are a major and growing problem for low- and…
Cost-Effectiveness Analysis | Policy/Regulation | Mental Health | Priority Setting/Ethics | Costing Methods | Technology Assessment | Child/Nutrition | Chronic Disease/Risk | Social Determinants | Health Systems | Economics/Finance | Food/Agriculture | Health/Medicine | Latin America & Caribbean -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Cost-Effectiveness Analysis | State-Transition | Mental Health | Priority Setting/Ethics | Costing Methods | Mathematical Models | Microsimulation | Decision Analysis | Chronic Disease/Risk | Health/Medicine | Latin America & Caribbean -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Cost-Effectiveness Analysis | Policy/Regulation | Mental Health | Preferences/Values | Health Outcomes | Evidence Synthesis | Technology Assessment | Chronic Disease/Risk | Health Systems | Business/Industry | Government/Law | Health/Medicine | Science/Technology | North America -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
Cost-Effectiveness Analysis | State-Transition | Mental Health | Health/Medicine | North America